Neurosense Therapeutics Ltd. NRSN 深 滬
已收盤 04-02 16:00:00 美东时间
0.83
+0.070
+9.21%
華盛通- 最 高0.8398
- 今 開0.77
- 成交量 9.90万股
- 最 低 0.76
- 昨 收 0.76
- 總市值 2771.92万
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 0.63
- 委 比 96.92%
- 總股本 3339.66万
- 歷史最高 8.18
- 量 比 1.32
- 振 幅 10.50%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.35) by 25.71 percent.
03-31 21:28
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks NeuroSense rescheduled its pre-New Drug Submission meeting with Health Canada to May 2026 to include additional clinical, biomarker, and survival analyses for PrimeC. Clinical and biomarker results from NeuroS
03-24 21:03
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.
03-10 18:40
NeuroSense Therapeutics Announces Availability Of Additional Long-Term Survival Data From PARADIGM Phase 2b Clinical Trial Evaluating PrimeC In Patients With ALS
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the
02-18 22:14
NeuroSense Therapeutics Granted Australia Patent For Its PrimeC
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian
02-09 22:23
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biote...
02-09 22:20
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- Neuro...
01-21 21:30
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical sta...
01-08 21:45
NeuroSense Therapeutics' Analysis From Phase 2 NST-AD-001 Trial Of PrimeC Combination In Alzheimer's Demonstrates Favorable Tolerability For PrimeC
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of the safety
2025-12-22 22:20
